Publications:

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.

Nature Communications

Pan, Min M; Wright, William C WC; Chapple, Richard H RH; Zubair, Asif A; Sandhu, Manbir M; Batchelder, Jake E JE; Huddle, Brandt C BC; Low, Jonathan J; Blankenship, Kaley B KB; Wang, Yingzhe Y; Gordon, Brittney B; Archer, Payton P; Brady, Samuel W SW; Natarajan, Sivaraman S; Posgai, Matthew J MJ; Schuetz, John J; Miller, Darcie D; Kalathur, Ravi R; Chen, Siquan S; Connelly, Jon Patrick JP; Babu, M Madan MM; Dyer, Michael A MA; Pruett-Miller, Shondra M SM; Freeman, Burgess B BB; Chen, Taosheng T; Godley, Lucy A LA; Blanchard, Scott C SC; Stewart, Elizabeth E; Easton, John J; Geeleher, Paul P

Publication Date: 2021-11-09

Variant appearance in text: PARP: E12E

PubMed Link: 34753908

Variant Present in the following documents:

• Main text

View BVdb publication page

Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens.

Oncoimmunology

Luo, Yong Y; Lin, Chaolong C; Zou, Yidi Y; Ju, Fei F; Ren, Wenfeng W; Lin, Yanhua Y; Wang, Yale Y; Huang, Xiaoxuan X; Liu, Huiling H; Yu, Zeng Z; Liu, Pingguo P; Tan, Guowei G; Yuan, Quan Q; Zhang, Jun J; Huang, Chenghao C; Xia, Ningshao N

Publication Date: 2020

Variant appearance in text: PARP: E12E

PubMed Link: 32117591

Variant Present in the following documents:

• Main text

View BVdb publication page